Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Sarcoma 1

Conditions

Cholangiocarcinoma 2Neoplasm Metastasis 1Gastrointestinal Stromal Tumors 1

Interventions

Specimen Handling 415Magnetic Resonance Spectroscopy 332pembrolizumab 261Biopsy 227Carboplatin 216Cisplatin 179Cyclophosphamide 174Paclitaxel 148Nivolumab 135Gemcitabine 130Radiotherapy 120Dexamethasone 105Bevacizumab 101fludarabine 95Radiation 94Fluorouracil 93Pemetrexed 88Doxorubicin 88Docetaxel 83Rituximab 82venetoclax 81durvalumab 81Oxaliplatin 81Leucovorin 76atezolizumab 68Lenalidomide 66Capecitabine 66Prednisone 65Etoposide 64Vincristine 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × pemigatinib × 30 days × Clear all
NCT07434843 2026-05-22

PEMIGIST

Dana-Farber Cancer Institute

Phase 2 Recruiting
24 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT06302621 2026-05-15

Pemigatinib + Afatinib in Advanced Refractory Solid Tumors

Massachusetts General Hospital

Phase 1 Recruiting
70 enrolled
Gastrointestinal

Neoplasm Metastasis, Cholangiocarcinoma

NCT06728410 2026-05-08

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Hoosier Cancer Research Network

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡